Efficacy of nicorandil in acute coronary syndrome

Efficacy of short term prescription of nicorandil on in-hospital outcomes of patients who admitted because of acute coronary syndrome without ST elevation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202189067N1

Enrollment

252

Registered

2012-03-01

Start date

2012-02-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome. Ischaemic heart disease

Interventions

Treatment - Drugs

Intervention 1: Interventional group: Oral Nicorandil is started at first day of admission 20 mg BID in addition to common treatment,then continued during hospitalization until last day. Intervention

Interventional group: Oral Nicorandil is started at first day of admission 20 mg BID in addition to common treatment,then continued during hospitalization until last day.

Control group:identical to that of common treatment including antithrombotic,antiplatelet and analgesics.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criterion:Non ST elevation acute coronary syndrome. Exclusion criteria: myocardial infarction with ST levation and Left Bundle Branch Block

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Response treatment. Timepoint: During hospitalization daily. Method of measurement: Physician visit.	—

Secondary

Measure	Time frame
Clinical side effect. Timepoint: During hospitalization daily. Method of measurement: Physician visit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Jadbabaei

Kermanshah university of medical sciences and health services

sara.jadbabaei@gmail.com+98 83 1836 2022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026